Stephan Gauldie, PhD
Partner, Managing Director, Head of Back Bay Canada
Stephan Gauldie is a founding member of Back Bay Life Science Advisors and head of Back Bay’s Canadian Operations. Dr. Gauldie helped build Back Bay’s integrated strategic advisory and investment banking offering for life science companies at every stage. Dr. Gauldie’s role emphasizes commercial assessment and forecasting, strategic franchise-building, M&A and licensing strategy, buy-side diligence, and exit planning with defensible, analysis-driven positioning for venture-backed companies.
Dr. Gauldie is also a member of Back Bay’s investment banking team, providing forecasting, valuation, market, and scientific analytics in sell-side transactions, buy-side engagements, and financing support.
He has more than 20 years of experience across drug development research, market analysis, and strategy consulting. Before joining Back Bay, Dr. Gauldie led the Commercial Research Group at Decision Resources. He was a Principal Analyst at Wood Mackenzie, leading teams that covered US and EU-based pharmaceutical companies, as well as CNS/Pain and Immunology therapeutic areas.
Dr. Gauldie obtained his doctorate in Neuropharmacology from the University of Edinburgh Medical School, in collaboration with GlaxoSmithKline’s Neurology and Gastrointestinal Center for Early Drug Discovery (CEDD) and completed a post-doctoral fellowship in the Department of Pharmacology at the same institution.
He holds undergraduate degrees in Medicinal Chemistry and Psychology from Queen’s University, Canada.
Select industry insights by Dr. Gauldie:
Roaring 20s Redux: The Next Decade of Gene Therapy Innovation
Best Practices for Successful Sell-Side Licensing, Partnering and M&A [Podcast]
Nature BioPharma Dealmakers: From Drug Target Inhibition to Degradation: a TACtical Strategy
Canadian Venture Capital-Funded Biotech Companies to Watch in 2023